DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624   The session ...

Amarin Corporation Plc (AMRN) reported first-quarter 2024 adjusted loss of 2 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 5 cents per share. The company had recorded an adjusted loss of 4 cents in the year-ago quarter.Total revenues were $56.5 million, which beat the Zacks Consensus Estimate of $51.0 million. However, revenues declined 34% from the year-ago quarter’s levels, owing to lower product revenues.Despite the better-than-expected results, shares of Amarin were ...

Financial Data and Key Metrics Changes - Amarin reported total net revenue of $56.5 million in Q1 2024, down from $86 million in Q1 2023, with U.S. product revenue declining to $48.1 million from $82.3 million due to generic competition [26][28] - The company maintained a gross margin of 55% on net product revenue, with a stable cash position of $308 million over the last seven quarters [27][29] Business Line Data and Key Metrics Changes - In Europe, net product revenue reached $1.9 million, reflecting a 35% increase compared to Q4 2023, driven by strong sales growth in Spain and the UK [26][27] - The number of patients on VAZKEPA therapy in Spain increased by 91% in Q1 2024 compared to Q4 2023, while the UK saw a 28% increase in the same period [12][14] Market Data and Key Metrics Changes - In the U.S., Amarin retained exclusive accounts representing over 50% of the IPE market, with stable market share for six consecutive quarters despite revenue declines [14] - In China, sales growth for VASCEPA increased by 100% in Q1 2024 compared to Q4 2023, indicating strong market potential [16] Company Strategy and Development Direction - Amarin is focused on enhancing the value of its business and maximizing patient uptake of VASCEPA and VAZKEPA, with a strong emphasis on intellectual property protection extending to 2039 [8][11] - The company aims to secure pricing reimbursement in five additional European markets in 2024, with ongoing efforts in Italy, France, and Germany [10][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential in Europe, particularly in Spain and the UK, despite the complexities of market access and reimbursement processes [39][41] - The company is committed to maintaining profitability in the U.S. while exploring opportunities for business development, particularly in Europe [60] Other Important Information - Amarin secured shareholder approval for a share repurchase program of up to $50 million, with plans to commence repurchases pending UK High Court approval [10][30] - The company reported a net loss of $10 million for Q1 2024, with a basic and diluted loss per share of $0.02 [28] Q&A Session Summary Question: When can we expect to see revenue from China? - Management highlighted that China is a significant market with unmet needs, and sales growth for VASCEPA increased by 100% in Q1 2024, with potential for national reimbursement listing [34][35] Question: What is the progress on the share buyback program? - Management confirmed that shareholder approval was achieved, and the next step is to secure UK High Court approval before commencing share repurchases [36][37] Question: Why has Amarin struggled with UK and EU product adoption? - Management acknowledged the complexities of reimbursement processes in Europe but expressed confidence in the new strategy and leadership driving progress [38][40] Question: What is the long-term future of the company? - Management emphasized a focus on growth in key EU5 markets and maintaining profitability in the U.S., supported by a strong cash position and reduced operating expenses [42][43] Question: Can you elaborate on the healthy women's citizens petition regarding fibrates in the U.S.? - Management stated that the petition aims to ensure patients are prescribed effective therapies, highlighting the lack of benefit from combining fibrates with statins [44][45]

Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK -- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdict ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fenofibrates, due to the fact that multiple clinical trials have proven fenofibrates have no clinical benefit when used in combination with statins to reduce cardiovascular disease (CVD) ri ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. compan ...

Core Insights - Amarin Corporation presented findings on the efficacy of VASCEPA/VAZKEPA in reducing Major Adverse Cardiovascular Events (MACE) in patients with varying Lipoprotein(a) [Lp(a)] levels and irrespective of baseline LDL-C levels [1][2][4] Group 1: Efficacy of VASCEPA/VAZKEPA - The analysis showed that high Lp(a) concentrations correlate with increased cardiovascular event risk, even when LDL-C levels are managed [2][4] - In a post hoc analysis of the REDUCE-IT study, 7,026 patients were evaluated, revealing a significant relationship between baseline Lp(a) levels and MACE risk, independent of LDL-C and triglycerides [3][4] - Icosapent ethyl (IPE) demonstrated a relative risk reduction of 21% for patients with Lp(a) ≥50 mg/dL and 25% for those with Lp(a) <50 mg/dL [5][4] Group 2: LDL-C and Cardiovascular Outcomes - The study also assessed the impact of IPE on cardiovascular outcomes among patients with different baseline LDL-C levels, specifically those below and above 55 mg/dL [6][7] - Among patients with LDL-C <55 mg/dL, the primary outcome rate was 16.2% in the IPE group compared to 22.8% in the placebo group, indicating a hazard ratio (HR) of 0.66 [7] - For patients with LDL-C ≥55 mg/dL, the rates were 17.4% in the IPE group versus 21.9% in the placebo group, with an HR of 0.76, showing consistent efficacy across both LDL-C subgroups [7][8] Group 3: Study Background and Significance - The REDUCE-IT study was a global cardiovascular outcomes trial involving 8,179 patients, designed to evaluate the effect of VASCEPA in high-risk patients with controlled LDL-C levels [10][11] - The findings reinforce the clinical benefit of IPE in reducing cardiovascular events, particularly in patients with elevated triglycerides and varying Lp(a) levels [5][8] - Amarin aims to enhance the understanding of cardiovascular risk management beyond traditional therapies, emphasizing the importance of ongoing research in this area [2][9]

Core Insights - Amarin Corporation's shares increased by 7.1% following positive updates regarding its intellectual property for Vazkepa in Europe [1] - A new patent from the European Patent Office extends Vazkepa's regulatory exclusivity until April 2039, adding eight years of commercial protection [2] - The validity of another existing patent for Vazkepa was upheld, which is crucial for maintaining competitive pricing in the healthcare sector [2] - Year-to-date, Amarin's shares have risen by 21.8%, significantly outperforming the industry average of 1.9% [3] Patent and Exclusivity - The new patent and the upheld patent claims are based on results from the REDUCE-IT study, which demonstrated that Vazkepa reduces cardiovascular death and revascularization risks [2] - The exclusivity granted by these patents allows Amarin to set drug prices without competition, which is vital for revenue generation [2] Market Performance - Vazkepa is approved in Europe for reducing cardiovascular event risks and as an add-on treatment for adults with high triglyceride levels [3] - The drug is also marketed in the U.S. under the name Vascepa, but has faced generic competition since 2020, leading to a 22% decline in sales last year [4] - Amarin has not provided revenue guidance for 2024 due to uncertainty regarding the impact of generic competition [4] Competitive Landscape - The company faces challenges in raising awareness for Vazkepa's cardiovascular risk reduction indication, which may further affect sales [4] - Other healthcare stocks with strong performance include ADMA Biologics, ANI Pharmaceuticals, and Ligand Pharmaceuticals, each showing significant earnings surprises and share price increases [5][6][7]

There was unambigously good news about the company's single commercialized medication.Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (AMRN 7.07%), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher in late-session trading on the stock market, eclipsing the basically flatlining S&P 500 index.A victory for VazkepaAmarin announced t ...